Biopharma AI
By
How Novo Nordisk and Deep Apple’s $812M AI-Powered Alliance Redefine the Future of Oral Obesity Drugs?
Key Highlights: A Bold Break from Incretin DependencyNovo Nordisk’s new alliance with Deep Apple Therapeutics marks a critical…
Can GenepoweRx and MGI Tech’s AI-Driven Genomic Partnership Transform Personalized Medicine in 2025?
Key Highlights: Strategic Alliance to Revolutionize Genomic MedicineIndian AI-driven startup GenepoweRx and China’s MGI Tech have joined forces…
Bexorg and Biohaven: Can Their AI-Driven Whole-Brain Discovery Platform Revolutionize CNS Drug Development?
Key Highlights: Strategic Collaboration to Transform CNS TherapeuticsBexorg, a techbio innovator focused on decoding the human brain, has…
Tevogen AI & Microsoft: Will Their AI & Generics Bet—and $10B Asset Strategy—Redefine U.S. Bioinnovation Infrastructure?
Key Highlights HQ Expansion to Power AI, Generics & Biosimilar VisionTevogen Bio Holdings Inc. (Nasdaq: TVGN) has more…
Can Catalio Capital’s $400 Million AI-Driven Life Sciences Fund Ignite a New Era of Biomedical Innovation Despite a Slow VC Market?
Key Takeaways Resilience in a Cooling VC ClimateCatalio Capital Management has successfully closed its fourth Nexus Fund at…
Is Portal Biotech’s $35M Series A Set to Redefine Proteomics With the World’s First AI-Powered Full-Length Single-Molecule Protein Sequencer?
Key Takeaways Transforming Protein Sequencing With AI and Nanopore InnovationPortal Biotech, a London-based pioneer in proteomics, is aiming…
